Primary treatment with vincristine, dactinomycin, and cyclophosphamide in nondysgerminomatous germ cell tumor of the ovary

Gynecol Oncol. 1989 Aug;34(2):155-8. doi: 10.1016/0090-8258(89)90132-7.

Abstract

Thirty-three patients with malignant nondysgerminomatous germ cell tumors were treated with vincristine/dactinomycin/cyclophosphamide regimen. Thirty-two patients were suitable for analysis. The overall cure rate was 68.7%. This is comparable to the cure rate observed in the cisplatin/vinblastin/bleomycin regimen. The roles of second-look laparotomy in malignant germ cell tumor are discussed.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Dactinomycin / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Teratoma / drug therapy*
  • Vincristine / administration & dosage

Substances

  • Dactinomycin
  • Vincristine
  • Cyclophosphamide

Supplementary concepts

  • VAC protocol